Saturday 17 October 2026
Export ZEPP’s income statement to Excel — free account
Zepp Health Corporation Sponsored ADR
ZEPP Technology Consumer Electronics
Zepp Health Corporation Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $258.9 million, up 41.8% from fiscal 2024. In the quarter to June 2026, revenue grew 6.93%, EPS fell 46.9%, free cash flow fell 103.7% and total debt rose 26.4%, each against the same quarter a year earlier.
3.04
0.16
−5.00%
Follow ZEPP
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
3.10 | 1.65 | 0.70 | 0.30 | |
P/FCF ratio |
194.68 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(29.69) | (16.67) | (7.38) | (3.21) | |
P/B ratio |
3.20 | 2.00 | 0.98 | 0.45 | |
Price to Tangible BV |
3.57 | 2.24 | 1.11 | 0.51 | |
EV/Sales |
3.13 | 1.66 | 0.79 | 0.40 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
49.18 | (32.02) | (15.87) | (8.14) | |
EV/FCF |
196.12 | (36.61) | (18.15) | (9.31) | |
Quick Ratio |
0.67 | 0.65 | 0.56 | 0.60 | |
Current Ratio |
1.09 | 1.02 | 0.88 | 0.90 | |
Net Debt/EBITDA |
(6.08) | (0.59) | (1.35) | (2.19) | |
Debt/Assets |
18.58% | 20.40% | 23.85% | 23.81% | |
Debt/Equity |
0.48 | 0.54 | 0.65 | 0.72 | |
Asset Turnover |
0.40 | 0.47 | 0.52 | 0.50 | |
Operating CF/Net income |
0.00 | 2.34 | 0.00 | 0.00 | |
Capex/Depreciation |
— | (0.09) | — | — | |
Interest Coverage |
(0.60) | (2.40) | (10.70) | (7.33) | |
Research and Development Expense of Revenue |
14.25% | 12.89% | 25.48% | 18.17% | |
Selling, General and Administrative Expense of Revenue |
25.08% | 32.06% | 46.55% | 38.55% | |
Intangible Assets out of Total Assets |
0.04 | 0.04 | 0.04 | 0.04 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(0.07) | (0.13) | (0.42) | (1.12) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(8.98%) | (9.32%) | (21.09%) | (52.78%) | |
Free Cash Flow Yield |
0.51% | (2.75%) | (6.20%) | (14.26%) | |
Revenue per Share |
4.79 | 5.36 | 3.25 | 4.01 | |
Operating CF per Share |
0.00 | (1.62) | 0.00 | 0.00 | |
Capex per Share |
0.00 | (0.02) | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | (1.64) | 0.00 | 0.00 | |
Cash per Share |
6.55 | 7.10 | 6.50 | 6.71 | |
Shareholders Equity per Share |
14.31 | 13.49 | 12.23 | 11.68 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
14.31 | 13.49 | 12.23 | 11.68 | |
Free Cash Flow |
— | (26.08) | — | — | |
Working Capital |
25.84 | 6.68 | (35.00) | (31.86) | |
Capital Expenditures |
— | (0.39) | — | — | |
Net Current Asset Value |
(48.32) | (56.78) | (79.17) | (92.19) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
66.29 | 69.60 | 58.94 | 78.58 | |
Average Payables |
68.62 | 65.92 | 59.99 | 87.25 | |
Average Inventory |
82.13 | 64.77 | 63.49 | 71.17 | |
Average Assets |
587.61 | 546.71 | 525.67 | 554.32 | |
Average Common Equity |
270.94 | 233.63 | 213.10 | 205.18 |
Columns are period end dates